Pathstone Family Office’s IGC Pharma IGC Stock Holding History

Pathstone Family Office’s Portfolio IGC Stock Details IGC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-1	Closed	–	–	977
2020 Q4	$0	Buy	+1	New	+$1	﹤0.01%	1233

Other funds holding IGC

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

IEFM

IQ EQ Fund Management Dublin 2, Ireland $1.32B AUM 31.52% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

CFA

Carroll Financial Associates Charlotte, North Carolina $1.88B AUM 20.52% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Vontobel Holding Zurich, Switzerland $29.1B AUM 22.79% 1-Year Est. Return

Dearborn Partners Chicago, Illinois $1.85B AUM 6.59% 1-Year Est. Return

Simplex Trading Chicago, Illinois $149B AUM 62.07% 1-Year Est. Return

Pathstone Family Office's IGC Position: Q1 2021 in Review

Pathstone Family Office sold out of IGC Pharma (IGC) in Q1 2021, closing a stake of 1 share.

Pathstone Family Office first reported a position in IGC in Q4 2020 and held it in 1 quarter. The position peaked at $0 in Q4 2020. 29 funds tracked by Wall St. Rank hold IGC as of Q1 2021.

Pathstone Family Office reported no remaining IGC Pharma position as of Q1 2021 after selling out during the quarter.
Pathstone Family Office sold 1 IGC Pharma share in Q1 2021.
Pathstone Family Office first reported a position in IGC Pharma in Q4 2020 and held it in 1 quarter.
Pathstone Family Office's IGC Pharma position peaked at $0 in Q4 2020.
29 funds tracked by Wall St. Rank held IGC Pharma as of Q1 2021.

Based on Pathstone Family Office's 13F filing for Q1 2021, filed 14 May 2021.